Liraglutide

CHEMBL4084119 Phase 4 معتمد Protein

Half-Life

13 hours

Bioavailability

—

Protein Binding

—

Molecular Weight

3751.0 g/mol

LogP

-3.4

Phase

4

A GLP-1 receptor agonist used to treat type 2 diabetes and obesity, and studied for cardiovascular and neuroprotective benefits. It mimics the natural GLP-1 hormone to stimulate insulin secretion, suppress appetite, and slow stomach emptying.

الوزن الجزيئي

3751,0000 g/mol

LogP

-3,40

TPSA

1510,00 Å²

قاعدة ليبينسكي للخمسة

راسب

المجالات العلاجية

Cardiovascular Disease Osteoporosis Alzheimer's Disease Bipolar Disorder Psoriasis Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Obesity Type 2 Diabetes Hypertension Major Depressive Disorder Heart Failure Atrial Fibrillation Leukemia

تصنيفات الأدوية

A — A - Alimentary Tract and Metabolism

آلية العمل

GLP-1 receptor agonist enhancing insulin secretion.

Pharmacokinetics (PK)

Half-Life 13 hours

Pharmacodynamics (PD)

الآلية

GLP-1 receptor agonist enhancing insulin secretion.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C)[C@@H](C)CC)C(=O)O

InChI

InChI=1S/C172H265N43O51/c1-18-20-21-22-23-24-25-26-27-28-29-30-37-53-129(224)195-116(170(265)266)59-64-128(223)180-68-41-40-50-111(153(248)199-115(62-67-135(232)233)154(249)204-120(73-100-44-33-31-34-45-100)159(254)214-140(93(11)19-2)167(262)192-97(15)146(241)201-122(76-103-79-183-108-49-39-38-48-106(103)108)157(252)203-118(72-90(5)6)158(253)212-138(91(7)8)165(260)200-110(52-43-70-182-172(177)178)149(244)184-81-130(225)193-109(51-42-69-181-171(175)176)148(243)187-84-137(236)237)196-144(239)95(13)189-143(238)94(12)191-152(247)114(58-63-127(174)222)194-131(226)82-185-151(246)113(61-66-134(230)231)198-155(250)117(71-89(3)4)202-156(251)119(75-102-54-56-105(221)57-55-102)205-162(257)124(85-216)208-164(259)126(87-218)209-166(261)139(92(9)10)213-161(256)123(78-136(234)235)206-163(258)125(86-217)210-169(264)142(99(17)220)215-160(255)121(74-101-46-35-32-36-47-101)207-168(263)141(98(16)219)211-132(227)83-186-150(245)112(60-65-133(228)229)197-145(240)96(14)190-147(242)107(173)77-104-80-179-88-188-104/h31-36,38-39,44-49,54-57,79-80,88-99,107,109-126,138-142,183,216-221H,18-30,37,40-43,50-53,58-78,81-87,173H2,1-17H3,(H2,174,222)(H,179,188)(H,180,223)(H,184,244)(H,185,246)(H,186,245)(H,187,243)(H,189,238)(H,190,242)(H,191,247)(H,192,262)(H,193,225)(H,194,226)(H,195,224)(H,196,239)(H,197,240)(H,198,250)(H,199,248)(H,200,260)(H,201,241)(H,202,251)(H,203,252)(H,204,249)(H,205,257)(H,206,258)(H,207,263)(H,208,259)(H,209,261)(H,210,264)(H,211,227)(H,212,253)(H,213,256)(H,214,254)(H,215,255)(H,228,229)(H,230,231)(H,232,233)(H,234,235)(H,236,237)(H,265,266)(H4,175,176,181)(H4,177,178,182)/t93-,94-,95-,96-,97-,98+,99+,107-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,138-,139-,140-,141-,142-/m0/s1

Molecular Formula

C172H265N43O51

HBD / HBA

54 / 55

الروابط القابلة للدوران

132

الذرات الثقيلة

266

PPARG (Peroxisome Proliferator-Activated Receptor Gamma) Agonist

Primary Target

MTOR (Mechanistic Target of Rapamycin) Other

Moderate Liraglutide + Insulin Glargine

Liraglutide combined with insulin glargine enhances glycaemic control but increases hypoglycaemia risk; the combination (IDegLira fixed-ratio product concept) requires insulin dose reduction.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

A GLP-1 receptor agonist used to treat type 2 diabetes and obesity, and studied for cardiovascular and neuroprotective benefits. It mimics the natural GLP-1 hormone to stimulate insulin secretion, suppress appetite, and slow stomach emptying.

GLP-1 receptor agonist enhancing insulin secretion.

Key pharmacokinetic parameters for Liraglutide: Half-life: 13 hours.

Yes, Liraglutide is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

Related Drugs

Same Drug Class

Metformin Small molecule Omeprazole Small molecule Pantoprazole Small molecule Lansoprazole Small molecule

Same Target

Metformin Small molecule Levothyroxine Small molecule Prednisone Small molecule Montelukast Small molecule

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4084119. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 16134956. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Liraglutide على PillFYI

البنية

بيانات سريعة

Class: A - Alimentary Tract and Metabolism
الصيغة الجزيئية: C172H265N43O51
المرادفات: 3

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Liraglutide

المجالات العلاجية

تصنيفات الأدوية

آلية العمل

Pharmacokinetics (PK)

Pharmacodynamics (PD)

البنية ثنائية الأبعاد

Cite this structure

Embed this structure

No side effects recorded

الأسئلة الشائعة

Related Drugs

Same Drug Class

Same Target

References & Data Sources

Embed This Widget